Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 16.3105 USD -0.12%
Market Cap: 238.9m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Anika Therapeutics Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anika Therapeutics Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Anika Therapeutics Inc
NASDAQ:ANIK
Selling, General & Administrative
-$78.7m
CAGR 3-Years
-5%
CAGR 5-Years
-22%
CAGR 10-Years
-19%
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%
No Stocks Found

Anika Therapeutics Inc
Glance View

Market Cap
239.7m USD
Industry
Biotechnology

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

ANIK Intrinsic Value
12.0834 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Anika Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-78.7m USD

Based on the financial report for Sep 30, 2024, Anika Therapeutics Inc's Selling, General & Administrative amounts to -78.7m USD.

What is Anika Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-19%

Over the last year, the Selling, General & Administrative growth was 15%. The average annual Selling, General & Administrative growth rates for Anika Therapeutics Inc have been -5% over the past three years , -22% over the past five years , and -19% over the past ten years .

Back to Top